APA (7th ed.) Citation

MP, M., E, G., A, S., MR, A., PC, B., SR, B., . . . JM, S. (2025). DNA immunotherapy for recurrent respiratory papillomatosis (RRP): Phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107. Nature communications, 16(1), 1518. https://doi.org/10.1038/s41467-025-56729-6

Chicago Style (17th ed.) Citation

MP, Morrow, et al. "DNA Immunotherapy for Recurrent Respiratory Papillomatosis (RRP): Phase 1/2 Study Assessing Efficacy, Safety, and Immunogenicity of INO-3107." Nature Communications 16, no. 1 (2025): 1518. https://doi.org/10.1038/s41467-025-56729-6.

MLA (9th ed.) Citation

MP, Morrow, et al. "DNA Immunotherapy for Recurrent Respiratory Papillomatosis (RRP): Phase 1/2 Study Assessing Efficacy, Safety, and Immunogenicity of INO-3107." Nature Communications, vol. 16, no. 1, 2025, p. 1518, https://doi.org/10.1038/s41467-025-56729-6.